Jefferies reiterates Arcutis stock Buy rating on Zoryve growth
Jefferies reiterated a Buy rating and $39.00 price target for Arcutis Biotherapeutics (ARQT) due to Zoryve's prescription growth, estimating Q3 2026 sales of $143M. The stock trades at $24.17, below analyst targets. Zoryve's Q3 growth moderated to 8-9% from 13-14% in Q2, with strong margins. Jefferies expects Q4 sales to improve seasonally and forecasts 2026 sales of $525-540M. ARQT reported Q2 2026 revenue of $129.9M, up 59% YoY, and turned profitable.
How this was made
The 30-second read
Why it matters
The reiteration of a Buy rating and a $39 target reinforces a positive narrative but does not introduce a material new catalyst.
Market read
Minor positive bias for ARQT; limited broader market impact.
What to watch
Potential competitive pressure from other PDE4 inhibitors and reimbursement uncertainties could temper upside.
Background
Arcutis recently posted Q2 revenue beat and moved toward profitability; analyst coverage is expanding.
Ticker impact
Jefferies reiterated a Buy rating and set a $39 price target for Arcutis Biotherapeutics, citing 8‑9% prescription growth for Zoryve in Q3 2026 and strong gross margins.
likely upward pressure as the market prices in the higher target and growth outlook
The rating and target are new analyst actions; no immediate catalyst beyond the note, so impact is limited.
Market effects
Highlights continued growth in dermatology biotech, may benefit peers with similar pipelines.
U.S. biotech sector sees modest positive sentiment from the upgrade.
Limited to investors tracking small‑cap biotech stocks.
Counterpoint
The upgrade may be premature if prescription growth slows further in the summer season.
Key entities
- companyArcutis Biotherapeutics Inc.
NASDAQ-listed biotech developing the Zoryve dermatology platform.
- analyst_firmJefferies
Equity research firm providing the rating and price target.
